| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FBXO32 |
| Uniprot No | Q969P5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-355aa |
| 氨基酸序列 | MPFLGQDWRS PGQNWVKTAD GWKRFLDEKS GSFVSDLSSY CNKEVYNKEN LFNSLNYDVA AKKRKKDMLN SKTKTQYFHQ EKWIYVHKGS TKERHGYCTL GEAFNRLDFS TAILDSRRFN YVVRLLELIA KSQLTSLSGI AQKNFMNILE KVVLKVLEDQ QNIRLIRELL QTLYTSLCTL VQRVGKSVLV GNINMWVYRM ETILHWQQQL NNIQITRPAF KGLTFTDLPL CLQLNIMQRL SDGRDLVSLG QAAPDLHVLS EDRLLWKKLC QYHFSERQIR KRLILSDKGQ LDWKKMYFKL VRCYPRKEQY GDTLQLCKHC HILSWKGTDH PCTANNPESC SVSLSPQDFI NLFKF |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FBXO32(Atrogin-1/MAFbx)重组蛋白的模拟参考文献示例(仅供参考，实际文献需通过学术数据库查询)：
1. **文献名称**：*FBXO32/Atrogin-1 mediates skeletal muscle atrophy through ubiquitination of MyoD*
**作者**：Sandri M. et al.
**摘要**：该研究阐明了FBXO32作为E3泛素连接酶复合物的底物识别亚基，通过泛素化标记转录因子MyoD，促进其蛋白酶体降解，从而在肌肉萎缩过程中调控肌细胞分化与蛋白水解平衡。
2. **文献名称**：*Structural insights into FBXO32 substrate recognition and its role in cancer cachexia*
**作者**：Li J. et al.
**摘要**：通过重组FBXO32蛋白的晶体结构解析，揭示了其F-box结构域与Skp1的结合模式，以及底物结合口袋的关键氨基酸残基，为靶向FBXO32的癌症恶病质治疗策略提供结构基础。
3. **文献名称**：*Recombinant FBXO32 expression enhances proteasome activity in cardiomyocytes under oxidative stress*
**作者**：Wang Y. et al.
**摘要**：研究利用重组FBXO32蛋白体外验证其在心肌细胞氧化应激模型中通过激活泛素-蛋白酶体通路，加速错误折叠蛋白的清除，但过度表达可能导致病理性心肌萎缩。
4. **文献名称**：*FBXO32 regulates mitochondrial dynamics via degradation of Mfn2 in muscular dystrophy*
**作者**：Gomes M.D. et al.
**摘要**：发现FBXO32通过泛素化线粒体融合蛋白Mfn2.影响线粒体网络稳定性，提示其在杜氏肌营养不良症中可能通过线粒体功能障碍加剧肌肉退化。
---
**注意**：以上为根据领域热点的模拟文献，真实研究请通过PubMed、Google Scholar等平台检索关键词(如"FBXO32 recombinant protein"或"Atrogin-1 ubiquitination")。
FBXO32. also known as Atrogin-1 or MAFbx, is a member of the F-box protein family that functions as a substrate-recognition component of the SCF (Skp1. Cullin, F-box) ubiquitin ligase complex. This protein plays a critical role in the ubiquitin-proteasome system (UPS), a primary pathway for targeted protein degradation in eukaryotic cells. Structurally, FBXO32 contains an N-terminal F-box domain, which mediates interaction with Skp1. and a C-terminal region responsible for substrate binding. Its expression is highly induced in skeletal and cardiac muscle during atrophy caused by disuse, fasting, or diseases like cancer, diabetes, and heart failure.
Originally identified as a muscle-specific E3 ligase, FBXO32 targets key proteins for degradation, including structural components like troponin I and myosin heavy chains, as well as signaling molecules such as calcineurin and MyoD. This activity links FBXO32 to the regulation of muscle mass, hypertrophy, and cellular stress responses. Notably, its upregulation in muscle wasting conditions has made it a biomarker for atrophy and a potential therapeutic target.
Recombinant FBXO32 protein is engineered for in vitro studies to investigate its substrate specificity, enzymatic activity, and interactions with UPS components. Researchers utilize it to screen small-molecule inhibitors or modulators that could mitigate excessive protein degradation in muscle-related disorders. Beyond muscle biology, FBXO32 has been implicated in cancer progression, where it may act as a tumor suppressor by degrading oncoproteins or paradoxically promote metastasis in certain contexts. Its role in cardiac remodeling and neurodegenerative diseases is also under exploration. The development of recombinant FBXO32 facilitates mechanistic studies and drug discovery efforts aimed at UPS dysregulation in diverse pathological states.
×
